Free Trial

This company has been marked as potentially delisted and may not be actively trading.

GX Acquisition (GXGX) Competitors

GXGX vs. VSTM, ABEO, RCKT, AQST, TRDA, HRTX, TERN, TNXP, NGNE, and CYRX

Should you be buying GX Acquisition stock or one of its competitors? The main competitors of GX Acquisition include Verastem (VSTM), Abeona Therapeutics (ABEO), Rocket Pharmaceuticals (RCKT), Aquestive Therapeutics (AQST), Entrada Therapeutics (TRDA), Heron Therapeutics (HRTX), Terns Pharmaceuticals (TERN), Tonix Pharmaceuticals (TNXP), Neurogene (NGNE), and Cryoport (CYRX).

GX Acquisition vs. Its Competitors

Verastem (NASDAQ:VSTM) and GX Acquisition (NASDAQ:GXGX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, community ranking, dividends and earnings.

Verastem's return on equity of -332.73% beat GX Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
VerastemN/A -332.73% -73.97%
GX Acquisition N/A -985.20%-6.02%

Verastem received 617 more outperform votes than GX Acquisition when rated by MarketBeat users. However, 100.00% of users gave GX Acquisition an outperform vote while only 65.36% of users gave Verastem an outperform vote.

CompanyUnderperformOutperform
VerastemOutperform Votes
619
65.36%
Underperform Votes
328
34.64%
GX AcquisitionOutperform Votes
2
100.00%
Underperform Votes
No Votes

GX Acquisition has lower revenue, but higher earnings than Verastem.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verastem$10M30.77-$87.37M-$3.20-1.75
GX AcquisitionN/AN/A-$49.26MN/AN/A

Verastem presently has a consensus price target of $13.63, suggesting a potential upside of 143.30%. Given Verastem's stronger consensus rating and higher possible upside, analysts plainly believe Verastem is more favorable than GX Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Verastem
0 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
3.00
GX Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Verastem had 1 more articles in the media than GX Acquisition. MarketBeat recorded 1 mentions for Verastem and 0 mentions for GX Acquisition. Verastem's average media sentiment score of 1.87 beat GX Acquisition's score of 0.00 indicating that Verastem is being referred to more favorably in the media.

Company Overall Sentiment
Verastem Very Positive
GX Acquisition Neutral

Verastem has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, GX Acquisition has a beta of 0.17, suggesting that its stock price is 83% less volatile than the S&P 500.

88.4% of Verastem shares are held by institutional investors. Comparatively, 61.7% of GX Acquisition shares are held by institutional investors. 2.1% of Verastem shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Verastem beats GX Acquisition on 11 of the 14 factors compared between the two stocks.

Get GX Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for GXGX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GXGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GXGX vs. The Competition

MetricGX AcquisitionPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$62.89M$6.88B$5.57B$8.51B
Dividend YieldN/A2.51%5.27%4.15%
P/E RatioN/A8.5026.7819.65
Price / SalesN/A263.11404.49152.18
Price / CashN/A65.8538.2534.64
Price / Book12.506.526.964.59
Net Income-$49.26M$143.48M$3.23B$248.23M

GX Acquisition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GXGX
GX Acquisition
N/A$1.75
-0.6%
N/A-45.7%$62.89MN/A0.00N/AGap Down
VSTM
Verastem
3.4707 of 5 stars
$5.90
-2.0%
$13.63
+130.9%
+53.0%$324.20M$10M-1.8550High Trading Volume
ABEO
Abeona Therapeutics
4.0761 of 5 stars
$6.27
-0.2%
$19.25
+207.0%
+34.2%$320.75M$3.50M-2.33N/AAnalyst Revision
RCKT
Rocket Pharmaceuticals
4.9487 of 5 stars
$2.96
+6.9%
$19.57
+561.2%
-87.2%$316.09MN/A-1.08240Trending News
Analyst Revision
Gap Down
High Trading Volume
AQST
Aquestive Therapeutics
1.6842 of 5 stars
$3.18
+13.2%
$10.14
+219.0%
+23.5%$315.86M$54.23M-7.07160Positive News
Analyst Revision
TRDA
Entrada Therapeutics
2.9076 of 5 stars
$8.24
+1.2%
$25.67
+211.5%
-53.9%$312.73M$172.22M5.18110Positive News
Analyst Downgrade
Gap Down
HRTX
Heron Therapeutics
3.8707 of 5 stars
$2.00
+3.6%
$5.50
+175.0%
-46.9%$305.13M$148.52M-11.11300Analyst Revision
TERN
Terns Pharmaceuticals
4.1215 of 5 stars
$3.49
+6.4%
$15.63
+347.7%
-51.4%$304.81MN/A-2.9640Positive News
TNXP
Tonix Pharmaceuticals
3.3336 of 5 stars
$40.45
+6.3%
$585.00
+1,346.2%
-70.7%$296.30M$10.04M-0.0150Trending News
Gap Down
NGNE
Neurogene
3.4784 of 5 stars
$20.56
+15.8%
$44.60
+116.9%
-52.9%$293.23M$925K-4.7390News Coverage
Analyst Forecast
Gap Down
CYRX
Cryoport
3.4085 of 5 stars
$5.84
+8.1%
$11.00
+88.4%
-35.5%$292.80M$232.13M-1.731,020Trending News
Insider Trade
Gap Down

Related Companies and Tools


This page (NASDAQ:GXGX) was last updated on 6/14/2025 by MarketBeat.com Staff
From Our Partners